The rising prevalence of asthma drives the value of the bronchial spasms treatment market size. The number of asthma cases was nearly 283 million in 2021. The prevalence of the disease is likely to grow at a rate of 4.0% in the forecast period of 2023-2031. With this growth rate, the number of cases expected in 2030 is approximately 403 million.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Bronchial spasms are among the most common pulmonary disorders. In bronchial spams, the muscles around the bronchial tubes contract or inflame and obstruct the airway flow. This leads to irregular or short breathing and, in extreme situations, can lead to death.
The most common symptoms of bronchial spasms include wheezing, pain in the chest, difficulty in breathing and coughing. The contraction and inflammation of bronchial muscles are due to the associated pulmonary disorders like emphysema, asthma, bronchitis, or chronic obstructive pulmonary disease (COPD).
Bronchial spasms are likely to affect children, older adults, and people with weakened immune systems. People suffering from other allergies like food allergies or eczema are also expected to develop bronchial spasms.
Early diagnosis of bronchial spasms is important for proper therapeutic intervention. The diagnosis is done using tests like CT scans, chest X-rays, mucus testing or other imaging tests. Spirometry is an important diagnostic test used to measure the amount of air inhaled and exhaled through the lungs.
Treatment interventions for bronchial spasms depend on the pathophysiology and the severity of the disease. The effective treatment strategies are administering inhaled steroids, use of , and changes in lifestyle patterns.
According to the bronchial spasms treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis Type
Market Breakup by Treatment Type
Bronchial Spasms Treatment Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The bronchial spasms treatment market is driven by the increasing prevalence and incidence of respiratory disorders like emphysema, asthma, chronic bronchitis, and chronic obstructive pulmonary disorder. In 2021, around 283 million people were diagnosed with asthma, which is why there is more demand for more air inhalers, facilitating market growth.
Technological advancements are one of the primary drivers attributing to the development of the market. Healthcare products are getting better and better with the rapidly evolving innovative technologies. For example, with the invention of smart inhalers, patients can poise their dosage and take it according to their suitability.
The additional factors supplementing the market growth include rising adoption of IoT devices, increasing geriatric population, and increased investments by the key players.
Short-acting bronchodilators account for the largest share of the global market. This can be attributed to its immediate therapeutic effect in treating acute or chronic bronchial spasms.
North America will hold a significant share of the bronchial spasms treatment market. This is due to the technological advancements, rising geriatric population, increasing awareness and more research and developmental activities.
There are several treatment strategies for the management of bronchial spasms. Through diagnostic studies, the healthcare provider provides the best possible treatment. The treatment of bronchospasms is done with bronchodilators. The bronchodilators are administered through air inhalers, nebulisers, or tablet dosage forms.
The bronchodilator type is prescribed to assess the extremity of the situation. Short-acting bronchodilators are generally defined in case of immediate or rapid effects. This type of medication can open the blocked pathways within minutes. Some examples of these medications are Levalbuterol and Albuterol.
The long-acting bronchodilators take longer time to show their therapeutic effects but effectively reduces the risk of bronchospasms in the near future. Some long-acting bronchodilators are Aclidinium, Arformoterol, Formoterol, Glycopyrrolate, Indacaterol, Olodaterol, Salmeterol, and Tiotropium.
In case of severe or chronic bronchitis, inhaled steroids are incorporated as a therapeutic intervention. The steroids reduce the inflammation around the bronchial muscles. The oral and intravenous routes are the optimal administration routes for steroids.
Tremendous efforts of scientists, researchers, and healthcare professionals will lead to innovative therapies that will lay the foundation for next-generation technologies.
Henceforth, all these novel treatments will help improve healthcare and the global economy. These new treatment strategies will majorly drive the growth of the global bronchial spasms treatment market in the forecast period.
With extensive research and development, novel treatment methods are being discovered, projected to boost the growth of the bronchial spasms treatment market. During the clinical trials, combination therapies proved excellent treatment sources due to their synergistic therapeutic action.
Incorporating two monotherapies, inhaled corticosteroids, and short-acting beta two agonists as a single combined therapy will provide dual therapeutic action. The corticosteroids help reduce inflammation in bronchial airways and potentiate short-acting bronchodilators' therapeutic response.
In 2022, Pantherics Inc., a key player, received funds of USD 255,000 from the National Institutes of Health. This will facilitate the clinical trials for a novel bronchospasms drug that will be used to manage asthma and other pulmonary disorders.
The clinical trials are also done to increase patient awareness and adherence to the prescribed medication schedule. For example, in 2022, Boehringer Ingelheim Pharmaceuticals and HealthPrize conducted a program to educate chronic obstructive pulmonary disorder patients about medication adherence.
Implementing technology in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for bronchial spasms therapies. Several ongoing clinical trials are emerging as a key driving factor for market growth and development.
The report gives an in-depth analysis of the key players involved in the bronchial spasms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Diagnosis Type||
|Breakup by Treatment Type||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Bronchial Spasms Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
18.104.22.168 Patent Status and Expiry
22.214.171.124 Timelines from Drug Development to Commercial Launch
126.96.36.199 New Drug Application
188.8.131.52.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
184.108.40.206 US FDA
220.127.116.11 EU EMA
18.104.22.168 INDIA CDSCO
22.214.171.124 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Bronchial Spasms Treatment Market
8.1 Global Bronchial Spasms Treatment Market Overview
8.2 Global Bronchial Spasms Treatment Market Analysis
8.2.1 Market Overview
126.96.36.199 Global Bronchial Spasms Treatment Market Historical Value (2016-2022)
188.8.131.52 Global Bronchial Spasms Treatment Market Forecast Value (2023-2031)
8.2.2 Global Bronchial Spasms Treatment Market by Diagnosis Type
184.108.40.206 Market Overview
220.127.116.11.1 Imaging Test
18.104.22.168.2 Spirometry Test
8.2.3 Global Bronchial Spasms Treatment Market by Treatment Type
22.214.171.124 Market Overview
126.96.36.199.1 Short-Acting Bronchodilators
188.8.131.52.1.1 Levalbuterol (Xopenex, Xopenex HFA)
184.108.40.206.1.2 Albuterol (AccuNeb, Proventil HFA, ProAir HFA, Ventolin HFA)
220.127.116.11.2 Long-Acting Bronchodilators
18.104.22.168.2.1 Aclidinium (Tudorza)
22.214.171.124.2.2 Arformoterol (Brovana)
126.96.36.199.2.3 Formoterol (Foradil, Perforomist)
188.8.131.52.2.4 Glycopyrrolate (Seebri Neohaler)
184.108.40.206.2.5 Indacaterol (Arcapta)
220.127.116.11.2.6 Olodaterol (Striverdi Respimat)
18.104.22.168.2.7 Salmeterol (Serevent)
22.214.171.124.2.8 Tiotropium (Spiriva)
126.96.36.199.3 Inhaled Steroids
188.8.131.52.4 Oral or Intravenous Steroids
8.2.4 Global Bronchial Spasms Treatment Market by Distribution Channel
184.108.40.206 Market Overview
220.127.116.11.2 Diagnostic Centres
8.2.5 Global Bronchial Spasms Treatment Market by Region
18.104.22.168 Market Overview
22.214.171.124.1 North America
126.96.36.199.3 Asia Pacific
188.8.131.52.4 Middle East and Africa
184.108.40.206.5 Latin America
9 North America Bronchial Spasms Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Bronchial Spasms Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific Bronchial Spasms Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America Bronchial Spasms Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa Bronchial Spasms Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global Bronchial Spasms Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Novartis International AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 GSK plc
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Merck & Co., Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 AstraZeneca plc
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 C. H. Boehringer Sohn Co. KG
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Teva Pharmaceutical Industries Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Viatris Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Sunovion Pharmaceuticals Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Amphstar Pharmaceuticals, Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Pfizer, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
16 Global Bronchial Spasms Treatment Market- Drug Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
Bronchodilators are the medications used for widening the obstructed or blocked bronchial pathways and thus helps in normal breathing.
Increasing prevalence of pulmonary disorders, technological advancements, increased research and developmental activities, and better awareness are the driving factors of the market.
Based on the diagnosis type, the market is segmented into spirometry tests and imaging tests, among others.
Based on the treatment type, the market is categorised into long-acting bronchodilators, short acting bronchodilators, inhaled steroids, and oral or intravenous steroids.
The distribution channels in the market are hospitals, diagnostic centres, and clinics, among others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is anticipated to hold a significant share of the market during the forecast period.
The bronchodilators help manage obstruction and inflammation of bronchial muscles caused due to the associated pulmonary disorders like emphysema, asthma, bronchitis, or chronic obstructive pulmonary disease (COPD).
The key companies involved in the market are Novartis International AG, GSK plc, Merck & Co., Inc., AstraZeneca plc, C. H. Boehringer Sohn Co. KG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sunovion Pharmaceuticals Inc., Amphstar Pharmaceuticals, Inc., and Pfizer, Inc., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.